Format

Send to

Choose Destination
Skin Therapy Lett. 2018 Nov;23(6):6-10.

Afamelanotide in the Treatment of Dermatologic Disease

Author information

1
Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA
2
Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA
3
Department of Dermatology, Beaumont-Farmington Hills, Farmington Hills, MI, USA

Abstract

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE), vitiligo, acne, and Hailey-Hailey disease. Its relatively low risk side effect profile makes it an attractive treatment option and also paves the way for innovative use in other disorders.

KEYWORDS:

acne; afamelanotide; alpha-melanocyte stimulating hormone; erythropoietic protoporphyria; Hailey-Hailey disease; polymorphic light eruption; solar urticaria; vitiligo

PMID:
30517779
Free full text

Conflict of interest statement

Dr. Hamzavi is an investigator for Incyte Corporation, Bayer, Clinuvel, Estée Lauder, Unigen Inc., and Ferndale Laboratories with grants received by the institution. Dr. Nahhas and Dr. Braunberger are sub-investigators for Bayer, Estée Lauder, Unigen Inc., and Ferndale Laboratories with grants received by the institution. Morgan McNeil has no conflicts of interest to declare. Dr. Nahhas and Dr. Braunberger were former sub-investigators for Ferndale Laboratories, Bayer, Estée Lauder, and Unigen Inc., with grants paid to the institution.

Supplemental Content

Full text links

Icon for Skin Therapy Letter
Loading ...
Support Center